Last updated: 03/29/2021 20:40:10
Patient‐Reported Outcome Measurement Information System (PROMIS) Physical Function
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: Qualitative Interviews to Evaluate the PROMIS Physical Function Item Bank for use in Oncology Clinical Trials
Trial description: The objective of this study is to conduct in-person qualitative interviews of subjects who have different tumor types to identify and assess relevant PROMIS physical function items that can be utilized in future studies. Health Research Associates (HRA) will conduct qualitative interviews in subjects with a variety of cancer types. PROMIS is a set of self‐report measurement tools, developed by the United States (US) National Institutes for Health (NIH). The most recent version of PROMIS Physical Function Item Bank contains 165 items assessing a range of abilities and its subset, a 45-item PROMIS Function Cancer Item Bank which contains questions relevant to subjects with cancer. Approximately 150 subjects with five tumor types will be recruited. HRA will conduct the interviews that will be audio-recorded for transcription and analysis. Five tumor types that will be focused on are Breast, Prostate, Non‐Small‐Cell Lung Cancer (NSCLC), Multiple Myeloma, and Diffuse Large B‐Cell (DLBCL) or Follicular Lymphoma. Interviews will be conducted in English language in private areas within clinic site or rented meeting facilities and will last approximately for 60-90 minutes.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Conduct qualitative patient interviews with a range of cancer patients across multiple tumor types to identify a subset of relevant PROMIS Physical Function items that can be utilized in future clinical trials
Timeframe: Approximately 90 minutes
Secondary outcomes:
Number of subject expressions of a given concept
Timeframe: Approximately 90 minutes
Number of interviews to reach saturation of concept
Timeframe: Approximately 90 minutes
Interventions:
Other: Qualitative Interviews
Other: PROMIS Physical Function Items
Enrollment:
1
Observational study model:
Cohort
Primary completion date:
2020-08-05
Time perspective:
Prospective
Clinical publications:
Not applicable
Medical condition
Neoplasms
Product
GSK2857916
Collaborators
Health Research Associates, Inc.
Study date(s)
December 2017 to May 2020
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Subject has a confirmed diagnosis of a primary tumor of one of the following: Breast Cancer, Prostate Cancer, NSCLC, Multiple Myeloma (excluding smoldering/asymptomatic multiple myeloma) and DLBCL or Follicular Lymphoma
- Subject is able to read, write, and speak English well enough to understand and complete Informed Consent Form (ICF) and take part in the interview process
- Subject has more than one current primary tumor
- Subject has a Stage 0 or in situ neoplasm
Inclusion and exclusion criteria
Inclusion criteria:
- Subject has a confirmed diagnosis of a primary tumor of one of the following: Breast Cancer, Prostate Cancer, NSCLC, Multiple Myeloma (excluding smoldering/asymptomatic multiple myeloma) and DLBCL or Follicular Lymphoma
- Subject is able to read, write, and speak English well enough to understand and complete Informed Consent Form (ICF) and take part in the interview process
- Subject has received treatment for their qualifying tumor within the prior 6 months, with the exception of treatment‐naïve subjects who have been diagnosed within the past 6 months
- Subject is at least 18 years of age
- Subject has an estimated life expectancy of 3 months or greater
Exclusion criteria:
- Subject has more than one current primary tumor
- Subject has a Stage 0 or in situ neoplasm
- Subject has known unstable and/or untreated brain metastasis
- Subject had major surgery within the last 30 days prior to enrolment that may be associated with changes in physical function. Open biopsy is considered a major surgery
- Subject has a current or past history of a personality disorder, bipolar disorder, schizophrenia or other psychotic disorder, obsessive compulsive disorder, cognitive disorder, post‐traumatic stress disorder, or other mental deficit
- In the opinion of the site investigator or study director, subject has any medical condition or disorder that could compromise his/her ability to give written informed consent and/or prevent or interfere with the Subject’s ability to successfully participate in a face‐to‐face interview and provide meaningful and non‐confounded information about their experience with their qualifying tumor
Trial location(s)
Location
GSK Investigational Site
Mountlake Terrace, Washington, United States, 98034
Status
Study Complete
Study documents
Protocol
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
2020-08-05
Actual study completion date
2020-08-05
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website